In patients with hemophilia A and inhibitory alloantibodies against factor VIII, various dosage schedules are used to obtain immune tolerance. In this study, we have evaluated the results of 13 years of low-dose immune tolerance induction and factors that are predictive of a positive result. The effect of immune tolerance induction in relation to age at inhibitor development, number of exposure days, age at start of therapy, maximum inhibitor titer, factor Vlll products involved, and virologic status were determined. We evaluated 24 patients with severe hemophilia A and inhibitors who were treated with regular infusions with low-dose (25 U/kg every other day) factor Vlll to obtain immune tolerance. In 21 of 24 patients (87%). immune tolerance induction was N HEMOPHILIA, the major obstacle to effective therapy is the development of specific alloantibodies against factor VIII, which rapidly inactivate the procoagulant activity of the infused factor VIII. Patients with high-titer antibodies' in particular do not respond to factor VI11 therapy, even if high doses of factor VI11 are given. Until the beginning of the 1980s, it was common practice to stop factor VIII therapy once an alloantibody (inhibitor) was detected. Factor VI11 therapy was limited to emergency situations because of a rapid anamnestic response occurring about 6 days after the start of factor VI11 infusion.*4 Only one observation of elimination of the anamnestic response to factor VI11 after infusion of high doses of factor VI11 in combination with cyclophosphamide and prednisone had been reported at that time.5 Since the report of successful treatment of inhibitor patients with high doses of factor VI11 in combination with activated prothrombin complex concentrate by Brackmann: several regimens for treatment of inhibitor patients have been published"" with the aim of inducing immune tolerance. The success of such treatment procedures is believed to be related to the dosage and frequency of factor VI11 given and the highest inhibitor
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In our hemophilia center, immune tolerance induction was introduced in 1981. ' Since that time, immune tolerance induction with low-dose factor VI11 has been started as soon as a persistent inhibitor is detected. Furthermore, immune tolerance induction was started in patients with preexisting inhibitors in whom factor VI11 had been stopped and who until then had been treated with activated prothrombin complex ~oncentrate'~ for bleeding episodes.
In this study, we evaluate the results of low-dose immune tolerance induction in inhibitor patients. Furthermore, we address the question of which factor was most predictive of a positive result.
I MATERIALS AND METHODS

Laboratory Assays
Plasma sampling. Plasma samples for factor VI11 and inhibitor assays were collected according to standard techniques: 4.5 mL of venous blood was drawn with a disposable needle into a siliconetreated Vacutainer tube (Venoject; Terumo Europe, Belgium) in which 0.5 mL of 3.8% (0.13 m o m ) sodium citrate was added. Immediately after collection, samples were carefully mixed and cen- successful. The response time was determined by two factors: the highest inhibitor level and the age at inhibitor development. In patients with maximum inhibitor levels of less than 40 Bethesda units (BU)/mL, immune tolerance was obtained sooner than in patients with inhibitor levels exceeding 40 BUlmL (P = .005). Patients in whom an inhibitor developed before the age of 2.5 years also tended to have a quick immune response (P = .014). Immune tolerance with low-dose factor Vlll is often successful in hemophilia A patients with inhibitors. Young children and patients with maximum inhibitors of less than 40 BU/mL show a relatively rapid response.
0 1995 by The American Society of Hematology. mfuged at 3,OOOg for 15 minutes at 4°C. The platelet-poor plasma was carefully pipetted off and stored in a plastic tube at -20°C.
All samples were analyzed at the coagulation laboratory of the University Hospital Utrecht (Utrecht, The Netherlands; Director, Dr J.W.N. Merman).
Inhibitor assay. Inhibitor measurements were performed using the Bethesda method as described by Kasper et al. I5 Inhibitor titers of 1 Bethesda unit (BU) per milliliter or more were considered positive based on our experience with recovery studies in more than 300 patients. In all patients with inhibitor levels of less than 1 BUI mL, normal recoveries were measured, and no clinical evidence of an inhibitor could be observed. In patients with a positive inhibitor test, blood samples for inhibitor measurement were subsequently taken every 4 to 8 weeks.
Factor Vlll assay. Factor VI11 assays were performed by the one-stage method based on the kaolin-activated partial prothrombin time and are expressed as a percentage of factor VIII present in pooled normal human plasma.I6
In vivo recovery. Blood samples for factor VI11 assays were taken before and 15 minutes after infusion with factor VIII. Recovery was defined as the level of factor VI11 measured and the expected level calculated by the method according to Lee et al." Recovery was assessed every 4 to 8 weeks in patients in whom the inhibitor level was less than 10 BU/mL. Virus screening. Screening for previous exposure to human immunodeficiency virus (HIV), hepatitis B, and hepatitis C was performed using standard techniques.
an inhibitor, antibody tests are performed as well. When an antibody titer of 1 BU/mL or more is measured, blood samples for repeated antibody testing are taken, and a factor VI11 recovery study is performed. Patients are considered to have a type A inhibitor when a recovery of 50% or less is measured, with or without clinical evidence of an inhibitor. Patients are considered to have transient (type B) inhibitors when the antibody titer of the second sample is less than 1 BUlmL and a normal recovery is found." Patients with type B inhibitors were excluded from the study. In the period from 1966 to 1980, persistent inhibitors (type A) were detected in 25 patients, whereas in the period from 1981 to 1993, in eight patients a persistent inhibitor was found. These 33 patients with persistent antibodies were eligible for the study. They form the majority (estimated at 90%) of inhibitor patients in The Netherlands. Nine patients were excluded from the study because they refused immune tolerance induction. Reasons for refusal were low bleeding frequency (less than two bleeding episodes per year), fear of viral transmission, problems with venous access, or psychological instability. Twentyfour patients were treated with immune tolerance induction. Informed consent was obtained from all patients. In eight patients, factor VI11 administration was never stopped once an inhibitor was detected, whereas in 16 patients, factor VI11 was discontinued. In 15 patients the inhibitor was detected before 1981 (during the time when the policy was to stop factor VIII); in one patient, in whom an inhibitor was detected in 1988, factor VI11 prophylaxis was temporarily stopped because of technical problems in obtaining venous access.
Dosage Regimen
When factor VI11 treatment was started because of an operation or a life-threatening bleeding and the inhibitor level was less than 10 BU/mL, an initial high dose of factor VI11 was given to neutralize the antibodies. The neutralizing dosage was calculated as follows':
where BW is body weight in kilograms; Ht, hematocrit; and I, inhibitor in BU/mL.
In this group of patients, the initial high dose was followed by infusion of 25 U factor VI11 per kilogram body weight (U FVIIY kg) twice daily for 1 to 2 weeks, depending on the clinical status of the patient and the anamnestic response to factor VIII. In patients in whom factor VIII treatment was started or continued with the sole aim of obtaining immune tolerance, the factor VI11 dosage was 25 Ukg every other day or three times per week, independent of the inhibitor titer. In very young children in whom venous access was difficult, factor VI11 was injected twice weekly.
When the antibody level decreased and factor VI11 recovery improved, or when an anamnestic response was lacking, factor VI11 was gradually tapered down each time the absolute factor VIII recovery was higher than 30%, until a standard prophylactic dosage of 10 to 15 U FVIII/kg was obtained.
Definition of Success
Immune tolerance induction was considered to be clinically successful when the inhibitor decreased to less than 2 BU/mL, with a factor VI11 recovery of at least 50% of normal, a factor VIII halflife time of 6 hours or more," and the absence of an anamnestic response after infusion with factor VIII.
Choice of Factor VIII Product
The choice of factor VIII therapy varied with time. Different factor VI11 products were used: cryoprecipitate and intermediate purified factor VIII, both virus-inactivated and nonvirus-inactivated, as well as monoclonal purified factor VIII.
Statistical Analysis
Probabilities of disappearance of the inhibitor over time were estimated with the product limit method of Kaplan and Meier and were compared using the log rank statistic. The time lapse until disappearance of the inhibitor was also examined by univariate and stepwise Cox regression analyses. All variables found to have a P value of less than .l0 in univariate analysis were considered candidate variables for multivariate analysis.
RESULTS
The study group consisted of 24 patients with severe hemophilia A. The patient data are summarized in Table 1 . The median age at inhibitor development was 5 years (range, 1 to 23 years). The median age at the onset of immune tolerance induction was 12 years (range, 1 to 43 years). Until 1980, cryoprecipitate was used in The Netherlands for replacement therapy. Inhibitors in the older patients developed after infusion of this product. Since then, inhibitors were seen after infusion of all kinds of factor VI11 products. Inhibitors developed after a median of less than 40 transfusions (range, 8 to 53). During immune tolerance induction, patients were seen at least every month. We checked the diaries kept by the patients against the amount of factor VI11 supplied to them. Based on these data, the compliance was almost 100%. None of the patients was lost for follow up during immune tolerance induction.
Immune tolerance induction was successful in 21 of 24 patients (87%). The success was obtained within 0.5 to 28 months (median, 1 year). Figure 1 shows a Kaplan-Meier plot of the presence of inhibitor for the whole group. The plot is almost linear in the first 2 years, indicating a constant chance of disappearance of inhibitor. Even after 2 years of therapy, there is a chance that the inhibitor will disappear. So far, immune tolerance induction has failed in three patients after a follow up of 36, 48, and 50 months, respectively. In two patients (patients 23 and 24), therapy failed even when therapy with high-dose intravenous gammaglobulin and cyclophosphamide as described by Nilsson et a19 was added. Patient 23 received three courses of this regimen without success, and factor VIII therapy was discontinued after 3 years; patient 24 received one course without success. In one patient (patient 8), immune tolerance induction has not yet been completed. Table 2 shows the bleeding frequencies before and after immune tolerance induction, as well as factor VI11 recoveries and half-life times. In 18 of 21 treated patients, the bleeding frequency has decreased. In three patients, a rather high bleeding tendency occurred, probably as result of traumata. In all patients, bleedings were less severe and disabling than before, and the bleeding tendency was quite comparable with hemophilia A patients without inhibitors. Nine patients underwent 15 surgical interventions without bleeding complications, and the amounts of factor VI11 given were similar to those given to patients who never had an inhibitor.
Univariate Cox regression analysis ( pendently predictive of the response to therapy: the highest inhibitor level [stepwise analysis, P = .005; risk ratio, 0.977; 95% confidence interval (CI), 0.962 to 0.9921 and the age (years) at inhibitor development ( P = .014; risk ratio, 0.797; 95% CI, 0.668 to 0.950). Patients with low maximum levels responded sooner. Figure 2 shows a Kaplan-Meier analysis months of treatment of the response time for patients with low (n = 12) versus high (n = 12) inhibitor levels. The median response time was 6 months for patients with a maximum inhibitor level less than 40 BU/mL, as compared with 19 months for patients with maximum inhibitor levels 240 BUlmL (log rank P < .Owl). Patients who developed an inhibitor at an early age tended to respond more quickly (Fig 3) . Whether therapy was started directly or many years after inhibitor development did not seem to make much difference. Treatment with a neutralizing dose at the start of immune tolerance induction did not improve the results. Furthermore, no difference in success was seen between HIV-positive (n = 4) and HIVnegative (n = 19) patients, and no influence of hepatitis B or C infection could be observed. Moreover, the type of factor VIII used to obtain immune tolerance did not affect the results.
Follow-up After Successful Immune Tolerance Induction
In 20 patients, factor VI11 was continued on a prophylactic basis once tolerance was obtained, and one patient was treated on a demand basis. In this patient, no anamnestic response of the inhibitory activity was seen, suggesting that immune tolerance was really obtained. (range, 4 to 162 months). In only one patient, recurrence of inhibitory activity was seen after 48 months, and this was easily managed by giving a second course of immune tolerance induction.
DISCUSSION
This study shows that immune tolerance induction in inhibitor patients (1) has a high success rate and ( 2 ) can be successfully achieved with a low-dose regimen, and (3) that the duration of treatment is determined by the maximum inhibitor level and the age at inhibitor development.
To gain insight into the nature of treatment effect, the criteria of response consisted of inhibitor titer, factor VI11 recovery and half-life times, and clinical data of response, such as bleeding frequency and the outcome of surgical interventions. A complete response was obtained in the majority of patients. In some patients, a suboptimal response was obtained, as evident from the factor VI11 recoveries and halflives. The treatment in these patients was considered clinically effective as they had a factor VI11 recovery of more than 60%, had no anamnestic response of the inhibitor titer, and could be adequately treated for bleeding episodes and surgical interventions. They were included in the group of successfully treated patients.
Since the introduction of immune tolerance induction in the beginning of the 1980s, success has been achieved with different dosage regimens.6"'.'3 Mostly high-dosage regimens are recommended, with daily dosages of 100 U FVIIV kg or more,8~'0~20 with or without the addition of corticosteroids," immunosuppressive drugs: or inhibitor adsorption by plasmapheresis." The success rate of these high-dosage Our low-dose schedule is also successful in patients with anamnestic responses over 40 BU/mL (9 of 12 patients, 75%); however, the time needed before success is obtained is substantially longer (1 2 to 28 months) compared with the group with low-titer inhibitors (3 to 9 months). At 3 years after start of therapy, no success was obtained in three patients. In two patients, factor VI11 was stopped. The KaplanMeier analysis suggests that continuation of factor VIII may eventually lead to success, although a long period of time may be needed before response is obtained.
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Definitive conclusions about the schedule of preference can only be drawn after prospective, randomized, controlled studies. A low-dose schedule could be part of such studies. Until such studies are performed, low-dose schedules may be indicated in individual patients, especially in those patients in whom immune tolerance induction has not been attempted because of the high costs of the other schedules.'* Inhibitors develop mostly in young patients, and in some of them, regular venous access may cause such technical problems that regular factor VI11 therapy must be temporarily interrupted. These patients can be treated later because no differences in success rate were found in this study between patients in whom factor VI11 was continued and patients in whom factor VI11 administration was interrupted.
Because in some patients, especially those with inhibitors of less than 5 BU/mL, the inhibitor would have disappeared spontaneously or with on-demand therapy, immune tolerance induction may not be required for all newly detected inhibitors. This could be a reason to postpone the start of regular factor VI11 therapy. However, the period of time before success is obtained will be uncertain and. in the case of on- demand therapy, will depend on bleeding episodes. This will introduce a greater risk of severe and disabling bleedings in the majority of patients. Therefore, the immediate start of immune tolerance induction in all patients with newly detected, persistent inhibitors should be considered.
Low-dose immune tolerance induction is often successful in hemophilia A patients with inhibitors. Time needed before success is obtained is related to the maximum inhibitor level and to the age at inhibitor development. Therefore, we postulate that all patients with inhibitors should be treated with low-dose factor VI11 to obtain immune tolerance. In patients in whom no response is seen during the first year, this regimen should be continued for a longer period of time. For personal use only. on April 19, 2017. by guest www.bloodjournal.org From
